PRINCETON, N.J., May 11 /PRNewswire/ -- Ranbaxy USA Inc., (RUSA), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announces the nationwide availability of new DisperMox(TM) (amoxicillin tablets for oral suspension) 600 mg tablets. DisperMox(TM) is the only amoxicillin in 200 mg, 400 mg, and 600 mg strengths that dissolves in water to form an oral suspension.
In March 2004, the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) announced new guidelines in prescribing antibiotics. These latest recommendations continue to name amoxicillin as first-line therapy for otitis media when antibiotic treatment is needed. However, the new recommendations suggest a higher dose of amoxicillin than was traditionally used. Along with the 200 mg and 400 mg strengths of DisperMox(TM), the new 600 mg dose will allow physicians to more easily achieve accurate dosing in accord with the new guidelines.
Dr. Laura Popper, named by New York Magazine as one of the top ten pediatricians in New York City, said, “With the release of the new 600 mg strength, I now have all of the options available for treating infections with amoxicillin. I frequently prescribe DisperMox(TM) for its dosing accuracy and convenience and the 600 mg strength provides a wider range of options for me and my patients’ parents.”
DisperMox(TM) can be mixed in as little as two teaspoonfuls of water for treatment, thus offering an accurate dose of medication and minimizing confusion when administered to a child. This antibiotic does not require refrigeration enabling both portability and convenience.
Jeffrey Thomas, Vice President, Brand Marketing and Sales at Ranbaxy USA Inc., said, “Ranbaxy’s launch of DisperMox(TM) 600 mg strength coincides with the American Academy of Pediatrics and the American Academy of Family Physicians new guidelines in treating otitis media. We believe that the 200 mg, 400 mg, and 600 mg strengths will give doctors and patients a wider range of options in accurate dosing.”
ABOUT RANBAXY LABORATORIES LIMITED
Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies” resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.
Ranbaxy USA Inc.
CONTACT: Charles M. Caprariello, Vice President, Business Development ofRanbaxy Inc., +1-609-720-5615; or Janine Lang of RF Binder Partners,+1-212-994-7525, for Ranbaxy USA Inc.
